NCT/Study#
NCT02744287 /
BP-012
A Phase 1/2 Feasibility, Safety, And Activity Study Of PSCA-Specific Chimeric Antigen Receptor Engineered T Cells (BPX-601) In Subjects With Previously Treated Advanced Solid Tumors
DISEASE GROUP:
Phase 1 Clinical Trials
current phase:
Phase I/II
STUDY STATUS:
Accepting Patients
Location:
Hackensack, NJ
For More information:
Call 201-518-3587
